Yourgene Health PLC Yourgene raises IONA® test awareness in Egypt

TIDMYGEN

Yourgene Health PLC

25 March 2019

Yourgene Health plc

("Yourgene" or the "Company")

Yourgene raises IONA(R) test awareness in Egypt with British Ambassador

Manchester, UK - 25 March 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, has held an event in Egypt to raise awareness of the IONA(R) test, a non-invasive prenatal DNA test for Down's syndrome, amongst the clinical community.

The event was attended by His Excellency Sir Geoffrey Adams, the British Ambassador to Egypt; and a number of key customers and medical professionals. Attendees heard from leading specialists in the prenatal field, including from the National Research Centre in Egypt and Ain Shams University's Faculty of Medicine.

British Ambassador in Egypt Sir Geoffrey Adams said: "The partnership between Egypt and the UK keeps on delivering new successes for both our countries. Today, British company Yourgene is bringing its latest technology to support the modernisation of the Egyptian healthcare system and offer world-class services for its citizens."

Lyn Rees, CEO of Yourgene, commented: "With a population of almost 100 million and a desire to offer high quality genetic analysis, we believe the market in Egypt could become a significant one for Yourgene going forward. We look forward to continuing to work with our local partners to deliver safe, fast and highly accurate prenatal screening solutions to pregnant women across Egypt."

Yourgene's IONA(R) test estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The test is performed on a maternal blood sample, containing traces of fetal DNA, which is then analysed using next generation DNA sequencing technology. The test is highly accurate and significantly reduces the number of women who are unnecessarily subjected to risky, invasive follow up procedures to diagnose Down's syndrome and other genetic conditions.

 
For more information, please contact: 
Yourgene Health plc                           Tel: +44 (0)161 
 Lyn Rees, Chief Executive Officer             667 1053 
 Barry Hextall, Chief Financial Officer 
 Joanne Cross, Head of Marketing 
 [e-mail] 
Vigo Communications                           Tel: [phone] 
 Ben Simons / Fiona Henson / Antonia Pollock   0238 
 [e-mail] 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

Yourgene Health's first commercialised products are non-invasive prenatal tests (NIPT) for Down's syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Yourgene Health's customer-focused products and services support all types of customer, irrespective of size, geography and market maturity. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRALFFSIVVIFFIA

(END) Dow Jones Newswires

March 25, 2019 03:01 ET (07:01 GMT)